Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combinations as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2100046383Phase 2Completed
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- May 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, docetaxel and Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Overall survival. Started May 2021; status: completed.
02
Drugs
camrelizumabdocetaxelRivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100046383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046383.